Lupin has launched Lamivudine and Zidovudine tablets (150 mg/300 mg) in US market after recieving final approval for its from the USFDA.
The compabination of Lamivudine and Zidovudine tablets (150 mg/300 mg) is used to treat HIV-1 infection and sold under brand name of Combivir being sold by Viiv Healthcare. Combivir had annual U.S sales of approximately US$ 275 million for the twelve months ending December 2011 (IMS Health sales data). The patent on the Combivir got expired on May 15th 2012. Apart from Lupin, TEva and Aurobindo Pharma has approvals for this combination products.We expect more players to join the generics market for this product.
....more info
The compabination of Lamivudine and Zidovudine tablets (150 mg/300 mg) is used to treat HIV-1 infection and sold under brand name of Combivir being sold by Viiv Healthcare. Combivir had annual U.S sales of approximately US$ 275 million for the twelve months ending December 2011 (IMS Health sales data). The patent on the Combivir got expired on May 15th 2012. Apart from Lupin, TEva and Aurobindo Pharma has approvals for this combination products.We expect more players to join the generics market for this product.
....more info